In a major international study, PTSD treatment-seeking was higher in high-income countries than in lower-income groups. Yet the high-income figure was still only a little above half. For affluent families, that raises a more useful question than whether money matters: what remains between being able to arrange care and receiving the right treatment?
Key findings
71,083: adults included across 26 World Mental Health Surveys in the analysis published in 2017.
3.9%: lifetime PTSD in the full study sample, compared with 5.6% among trauma-exposed respondents.
53.5%: reported treatment-seeking in the high-income country group.
28.7% and 22.8%: corresponding figures in upper-middle-income and low/lower-middle-income groups.
These are historical study findings. Country income is not individual wealth, and seeking treatment is not the same as recovering. [1]
Prosperity did not eliminate the treatment gap
Source: Koenen and colleagues, 2017. The groups describe participating countries’ income classifications, not respondents’ personal assets or income. [1]
The comparison does not suggest that resources are irrelevant. It shows a substantial association between country-income group and treatment-seeking. The unresolved question is why a gap remained in the better-resourced group. Recognition, service availability, and willingness to seek help are separate issues that need their own evidence.
For high-net-worth families, the question becomes more specific. When cost is less restrictive, what role do privacy, professional responsibilities, family involvement, and care coordination play? The study does not quantify those barriers among wealthy individuals. A survey designed for that population would need to ask about them directly.
A recent fact sheet can contain older data
WHO updated its PTSD fact sheet on September 11, 2026, but its central prevalence and treatment-gap statements cite earlier research, including the 2017 analysis. The updated page is a current publication. The underlying survey findings are not newly collected 2026 observations. [2]
This matters when a familiar statistic appears in a new headline. The publication date, observation period, and date of an interpretation are different. A recent review can confirm that an older estimate remains relevant without making it a new discovery.
The same principle applies to a provider’s evidence page. A recent update date does not establish that an older study was repeated in the provider’s setting or among patients resembling the person considering treatment. The study’s population and methods still need to be inspected.
Exposure, PTSD, and treatment are different measures
| Figure | Meaning | Not equivalent to |
|---|---|---|
| 3.9% | Lifetime PTSD in the full study sample | Current prevalence in every country |
| 5.6% | Lifetime PTSD among trauma-exposed respondents | Risk after every type of event |
| 53.5% | Treatment-seeking in the high-income group | Successful treatment or a millionaire survey |
| 71,083 | Adults included across the surveys | A new 2026 sample |
The 3.9% and 5.6% findings use different denominators. They are not contradictory estimates, and neither means that most trauma-exposed people developed PTSD. Preserving the denominator is essential when a statistic is used to explain the scale of a condition. [1]
A person’s difficulties should not be minimized because others recover after adverse experiences. Equally, an adverse experience should not automatically become a diagnosis. Assessment needs to consider symptoms, functioning, history, and current circumstances rather than a general population probability.
Co-occurring substance use should not end the discussion
The US National Center for PTSD summarizes evidence that people with PTSD and substance-use disorder can benefit from appropriately delivered trauma-focused treatment. It recommends offering evidence-based care for both conditions rather than treating one diagnosis as an automatic barrier to addressing the other. [3]
This is not an instruction for every patient to begin the same intervention immediately. Safety, medical stability, preferences, and the clinical formulation still matter. The point is that a blanket rule should not replace assessment of the individual and the available treatment options.
A private program should explain how clinicians coordinate the two areas, what the sequencing is intended to achieve, and how progress is measured. A full calendar of separate appointments is not the same as a coherent plan.
The center’s synthesis discusses Project Harmony, which incorporated 36 randomized trials. It favors trauma-focused approaches integrated with, or delivered alongside, appropriate substance-use treatment, while acknowledging limitations including substantial dropout in parts of the evidence. That does not generate a success rate for every clinic describing itself as trauma-informed. [3]
Measure both conditions and the person’s life
| PTSD | Substance use | Shared outcomes |
|---|---|---|
| Trauma-related symptom change | Use, harms, and disorder symptoms | Functioning and quality of life |
| Defined response or remission | Agreed recovery goals | Patient-defined priorities |
| Assessment at stated times | Sustained progress and recurrence | Follow-up, completion, and adverse outcomes |
This table proposes what to measure; it does not contain patient results. Separate condition measures can show whether progress in one area accompanies improvement in the other. Shared outcomes explain whether the changes matter in ordinary life.
A report should also identify who entered treatment, who completed it, and who was reached afterward. A favorable result among respondents does not establish the outcome for people who could not be contacted. Missing follow-up should remain visible rather than disappear from the denominator.
Why this matters for affluent and mobile families
Living in Switzerland, the UAE, or the United States does not identify someone as wealthy. Nor does an individual’s wealth reveal where they received care. A person using services in several countries may have a treatment history that national averages cannot describe.
For that family, the useful comparison is between proposed pathways. Who explains the assessment? Which intervention addresses the identified difficulties? Who coordinates care when recommendations differ? How will the next clinician receive an accurate account of treatment and response?
Professional success should not determine whether a reported difficulty deserves assessment. A person may maintain substantial responsibilities while seeking help. Conversely, stepping back from those responsibilities can be consistent with meaningful recovery. Outcome measures should reflect the person’s health and priorities rather than status alone.
Privacy and measurement can be considered together
A public-facing professional may place a high value on confidentiality. That does not mean outcomes must be replaced with anonymous testimonials or vague assurances. A provider can explain its measures, follow-up schedule, and reporting methods without revealing an identifiable patient’s story.
Small or recognizable patient groups need particular care in research design. A combination of profession, nationality, age, circumstances, and dates can identify someone even without a name. This article uses no patient records or case histories. Any future patient research would need appropriate ethical and privacy safeguards.
The editorial objective should be useful aggregate evidence, not a dramatic anecdote about a recognizable individual. An affluent audience is a reason to take confidentiality seriously, not a reason to loosen the standards for outcome claims.
What to ask before committing to treatment
Start with the assessment and the proposed clinical rationale. Ask what has been identified, which alternatives were considered, and how the suggested intervention relates to published evidence. Where several conditions coexist, the explanation should show how the plan brings them together rather than presenting unrelated specialty labels.
Then ask about review. What baseline will be recorded? Which changes would support continuing the plan, and which would prompt reassessment? Symptoms, functioning, adverse effects, and the patient’s priorities should be considered together. The final day of a stay is only one point in that process.
Finally, clarify the transition home. For someone returning to another country or a demanding role, who remains responsible for follow-up? What information will be shared with permission? The handover should be planned rather than rely on an assumption that another clinician will reconstruct the record.
What the numbers cannot tell us
The international study does not provide current national league-table scores or a high-net-worth treatment rate. Treatment-seeking is not adequacy, completion, or recovery. The clinical synthesis supports specified approaches under appropriate conditions, not every service using the phrase trauma-informed.
No private-provider comparison, wealth-effect estimate, or THE BALANCE outcome calculation is presented. Historical findings are retained with their original dates rather than extrapolated to present-day populations.
The bottom line
Better-resourced countries showed higher PTSD treatment-seeking, not universal access. For affluent families, obtaining an appointment is the beginning of the evidence trail. The next questions concern an appropriate assessment, coordinated treatment, and an honest account of progress after care begins.
For journalists
Key comparison: 53.5% treatment-seeking in the high-income country group versus 28.7% and 22.8% in the two lower-income groupings.
Important caveat: these are findings from a 2017 publication, not a 2026 survey or a study of wealthy individuals.
Suggested attribution: THE BALANCE analysis of published PTSD access and co-occurring-treatment evidence.
Methodology and sources
This narrative analysis keeps lifetime prevalence, treatment-seeking, and clinical outcomes separate. It reproduces published estimates without pooling the survey and trial evidence. The September 2026 WHO update is distinguished from the older research it cites.
